Literature DB >> 19679235

Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology.

Laurent Dortet1, Marie-Cécile Ploy, Claire Poyart, Josette Raymond.   

Abstract

We have studied 457 Streptococcus pneumoniae isolated in 2007 from adults and children. For all isolates, both latex agglutination and molecular capsular typing were performed. Antibiotic resistance patterns were determined. S. pneumoniae 19A was the most frequently isolated serotype (34.7%) both in children and adults. It represented 12.8% of the strains isolated from invasive infections in adults and 27.0% in children and 63.6% (110/173) of strains isolated from acute otitis media. Between children and adults, no difference concerning antibiotic susceptibility was observed for penicillin, amoxicillin, cefotaxime, and erythromycin in strains isolated from invasive diseases. Comparing antibiotic susceptibilities according to the serotype, the 19A isolates appeared to be the least susceptible to penicillin (3.2%) and erythromycin (4.5%), followed by serotypes 19F and 14. We confirm the predominance of serotype 19A among S. pneumoniae responsible for invasive and noninvasive diseases either in children or adults in France.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679235     DOI: 10.1016/j.diagmicrobio.2009.05.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  14 in total

1.  Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine.

Authors:  N Grall; O Hurmic; M Al Nakib; M Longo; C Poyart; M-C Ploy; E Varon; J Raymond
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-18       Impact factor: 3.267

2.  Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta.

Authors:  Leah J Ricketson; Otto G Vanderkooi; Melissa L Wood; Jenine Leal; James D Kellner
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

3.  A decade-long surveillance of nasopharyngeal colonisation with Streptococcus pneumoniae among children attending day-care centres in south-eastern France: 1999-2008.

Authors:  B Dunais; P Bruno-Bazureault; H Carsenti-Dellamonica; P Touboul; C Pradier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-25       Impact factor: 3.267

4.  Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children.

Authors:  C Hays; Q Vermee; A Agathine; A Dupuis; E Varon; C Poyart; M-C Ploy; J Raymond
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-20       Impact factor: 3.267

5.  Recent trends in epidemiology of invasive pneumococcal disease in Poland.

Authors:  A Skoczyńska; A Kuch; E Sadowy; I Waśko; M Markowska; P Ronkiewicz; B Matynia; A Bojarska; K Wasiak; A Gołębiewska; M van der Linden; W Hryniewicz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-05       Impact factor: 3.267

6.  Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly E Steed; Céline Vidaillac; Patricia Winterfield; Donald Biek; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

7.  Streptococcus pneumoniae vaccination strategies and its expected impact on penicillin non-susceptibility in children under the age of five: Let's recap!

Authors:  Hiba Sabbar; Chafik Mahraoui; Magdalena Bastìas Garcià; Imane Jroundi
Journal:  Vaccine X       Date:  2022-05-14

8.  Evidence of a clonal expansion of Streptococcus pneumoniae serotype 19A in adults as in children assessed by the DiversiLab® system.

Authors:  O Hurmic; N Grall; M Al Nakib; C Poyart; S Grondin; M-C Ploy; E Varon; J Raymond
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-15       Impact factor: 3.267

9.  Is there a potential role for protein-conjugate pneumococcal vaccine in older adults?

Authors:  Iman Ridda; Daniel M Musher
Journal:  Australas Med J       Date:  2012-04-30

10.  Laboratory surveillance of invasive pneumococcal disease in New South Wales, Australia, before and after introduction of 7-valent conjugate vaccine: reduced disease, but not antibiotic resistance rates.

Authors:  S Oftadeh; H F Gidding; G L Gilbert
Journal:  Epidemiol Infect       Date:  2012-09-25       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.